Skip to main content

Peer Review reports

From: Cost-effectiveness of brentuximab vedotin in advanced stage Hodgkin’s lymphoma: a probabilistic analysis

Original Submission
3 Apr 2020 Submitted Original manuscript
20 Apr 2020 Reviewed Reviewer Report
7 May 2020 Reviewed Reviewer Report
10 May 2020 Reviewed Reviewer Report
16 Jul 2020 Author responded Author comments - Adam J N Raymakers
Resubmission - Version 2
16 Jul 2020 Submitted Manuscript version 2
20 Jul 2020 Reviewed Reviewer Report
20 Jul 2020 Reviewed Reviewer Report
1 Aug 2020 Reviewed Reviewer Report
25 Aug 2020 Author responded Author comments - Adam J N Raymakers
Resubmission - Version 3
25 Aug 2020 Submitted Manuscript version 3
31 Aug 2020 Reviewed Reviewer Report
Resubmission - Version 4
Submitted Manuscript version 4
Publishing
1 Sep 2020 Editorially accepted
13 Oct 2020 Article published 10.1186/s12885-020-07374-3

You can find further information about peer review here.

Back to article page